<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of bacterial meningitis caused by specific pathogens in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of bacterial meningitis caused by specific pathogens in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of bacterial meningitis caused by specific pathogens in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodrigo Hasbun, MD, MPH, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan R Tunkel, MD, PhD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bacterial meningitis is a medical emergency, and immediate steps must be taken to establish the specific cause and initiate effective therapy. The mortality rate of bacterial meningitis approaches 100 percent and, even with optimal therapy, there is a high failure rate.</p><p>The possible presence of bacterial meningitis is suggested by the symptoms of fever, altered mental status, headache, and nuchal rigidity. Although one or more of these findings are absent in many patients with bacterial meningitis [<a href="#rid1">1-4</a>], virtually all patients (99 to 100 percent) have at least one of the classic triad of fever, neck stiffness, and altered mental status [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p>The treatment and prevention of bacterial meningitis caused by specific pathogens will be reviewed here. The epidemiology, pathogenesis, clinical features, diagnosis, initial management, and use of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for the treatment of bacterial meningitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1289.html" rel="external">"Pathogenesis and pathophysiology of bacterial meningitis"</a> and  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">APPROACH TO THERAPY</span><span class="headingEndMark"> — </span>There are a number of general principles of antimicrobial therapy in patients with bacterial meningitis. The most important initial issues are avoidance of delay in administering therapy and the choice of drug regimen. Intravenous antimicrobial therapy should be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography scan of the head is indicated to be performed before LP, immediately after blood cultures are obtained. Adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> should be given shortly before or at the same time as the first dose of antimicrobials, when indicated. General principles of initial therapy and selection of empiric antibiotic therapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults", section on 'General principles of therapy'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">THERAPY FOR SPECIFIC PATHOGENS</span><span class="headingEndMark"> — </span>The prevalence of various pathogens in bacterial meningitis varies by region of the world. Among adults with bacterial meningitis in the United States, <em>S. pneumoniae</em> and <em>Neisseria meningitidis </em>are the most common infecting organisms [<a href="#rid3">3,5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults", section on 'Incidence'</a>.)</p><p>The following treatment recommendations are in agreement with the 2004 Infectious Diseases Society of America (IDSA) guidelines, with some updates, for the management of bacterial meningitis and the 2017 IDSA guidelines for health care-associated ventriculitis and meningitis [<a href="#rid7">7,8</a>]. Since there are limited randomized trials regarding the therapy of specific causes of bacterial meningitis, treatment recommendations are based upon in vitro susceptibility and pharmacodynamic data as well as accumulated clinical experience.</p><p>Directed therapy against a specific organism is recommended when the clinical presentation and results of the cerebrospinal fluid (CSF) Gram stain are unequivocal  (<a class="graphic graphic_table graphicRef75922" href="/z/d/graphic/75922.html" rel="external">table 1C</a>) or the cultures are already positive  (<a class="graphic graphic_table graphicRef81209" href="/z/d/graphic/81209.html" rel="external">table 1A</a>) [<a href="#rid7">7-9</a>]. If, on the other hand, empiric therapy is begun, the regimen should be adjusted, if necessary, once the culture results are available  (<a class="graphic graphic_table graphicRef81209" href="/z/d/graphic/81209.html" rel="external">table 1A</a>). For the targeted regimen, agents should penetrate into the CSF to attain adequate concentrations to kill the meningeal pathogen rapidly, and the patient's isolate should demonstrate in vitro susceptibility [<a href="#rid8">8</a>]. Recommended dosages for use in patients with normal renal and hepatic function are shown in the table  (<a class="graphic graphic_table graphicRef60707" href="/z/d/graphic/60707.html" rel="external">table 1B</a>).</p><p>The duration of therapy for meningitis in adults has not been subjected to rigorous trials in the United States or other developed countries. The recommendations in the following sections reflect general consensus and are fairly conservative. However, a longer course may be warranted when complicating features are present or the clinical response is unusually slow. On the other hand, shorter courses (eg, single doses of depot <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a> or conventional <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) have been successful in the management of epidemic meningococcal meningitis in resource-limited countries. </p><p class="headingAnchor" id="H8"><span class="h2">Streptococcus pneumoniae</span><span class="headingEndMark"> — </span><em>S. pneumoniae</em> is the most common cause of meningitis in adults, particularly in older adults [<a href="#rid3">3,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults", section on 'Incidence'</a>.)</p><p>In the past, the conventional approach to the treatment of pneumococcal meningitis was the administration of penicillin alone for two weeks at a dose of four million units intravenously (IV) every four hours in patients with normal renal function. Good results were also obtained with a third-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> [<a href="#rid7">7</a>].</p><p>However, the widespread emergence of penicillin-resistant pneumococcus has made penicillin an inappropriate empiric therapy without proof of in vitro susceptibility. Although many third-generation cephalosporins have good in vitro activity against strains of pneumococcus that have intermediate susceptibility to penicillin (minimum inhibitory concentration [MIC] 0.12 to 1.0 mcg/mL) according to the cutoffs used prior to 2008, reports have raised the possibility of clinical failure when cephalosporin resistance coexists with penicillin resistance  (<a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">table 2</a>) [<a href="#rid10">10</a>]. In 2008, the Clinical and Laboratory Standards Institute removed the "intermediate" susceptibility category (MIC 0.12 to 1 mcg/mL) for the penicillin breakpoints of meningeal isolates of <em>S. pneumoniae</em>, such that all meningeal isolates with an MIC ≥0.12 are considered resistant. (See  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H44192873"><span class="h3">First-line regimens</span><span class="headingEndMark"> — </span>Initial empiric therapy of <em>S. pneumoniae</em> in patients with normal renal function includes <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (15 to 20 mg/kg IV every 8 to 12 hours) <strong>plus</strong> either <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g IV every 12 hours) or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g IV every 4 to 6 hours) [<a href="#rid7">7</a>]. In countries where the incidence of ceftriaxone-resistant pneumococcus (≥1.0 mcg/mL) is &lt;1 percent, it is appropriate to use ceftriaxone monotherapy for empiric coverage, although some authorities would recommend continuation of dual therapy pending in vitro susceptibility testing [<a href="#rid11">11</a>]. </p><p>In patients with isolates that are susceptible to penicillin (MIC ≤0.06 mcg/mL), <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (4 million units IV every four hours) or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> can be used instead of a third-generation cephalosporin, although it is also reasonable to continue therapy with a third-generation cephalosporin given the excellent efficacy, convenient dosing, and affordability of these agents. </p><p>If the isolate is resistant to penicillin (MIC ≥0.12 mcg/mL) but is susceptible to third-generation cephalosporins (MIC &lt;1.0 mcg/mL), <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g IV every 12 hours) or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g IV every 4 to 6 hours) is the preferred drug. Although some retrospective studies have advocated cephalosporin monotherapy for organisms with MICs up to 1.0 mcg/mL for cefotaxime or ceftriaxone [<a href="#rid12">12,13</a>], it seems more prudent to use the lower breakpoint (ie, less than 1.0 mcg/mL) [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a>, in combination with a third-generation cephalosporin, should be continued if there is penicillin resistance (MIC ≥0.12 mcg/mL) and an MIC ≥1.0 mcg/mL to third-generation cephalosporins  (<a class="graphic graphic_table graphicRef81209" href="/z/d/graphic/81209.html" rel="external">table 1A</a>)</p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is erratic in its penetration into the CSF and may be ineffective as monotherapy in pneumococcal meningitis. Nevertheless, it is recommended that vancomycin (15 to 20 mg/kg IV every 8 to 12 hours if renal function is normal) be given with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> in the initial treatment of pneumococcal meningitis until susceptibility results are available [<a href="#rid7">7</a>]. The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60 mg/kg. Serum trough concentrations of vancomycin should range from 15 to 20 mcg/mL. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a>.)</p><p>As noted above, early IV administration of glucocorticoids (usually <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>) has been evaluated as adjunctive therapy in an attempt to diminish the rate of hearing loss and other neurologic complications as well as mortality in adults patients with pneumococcal meningitis in high-income countries. Specific recommendations regarding the use of dexamethasone as adjunctive therapy for bacterial meningitis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p>In patients receiving adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, the diminished CSF inflammatory response after dexamethasone administration may reduce CSF <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> penetration and delay CSF sterilization. However, in a study of 14 patients, the administration of IV vancomycin (15 mg/kg loading dose, followed by a continuous infusion of 60 mg/kg per day) led to mean serum and CSF vancomycin concentrations of 25.5 and 7.9 mcg/mL, respectively, indicating that significant CSF concentrations can be attained with appropriate dosing [<a href="#rid14">14</a>]. If dexamethasone is given, some experts recommend empiric <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (600 mg orally or IV once daily) in addition to vancomycin, since its CSF penetration is unaffected by dexamethasone and it is synergistic with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> against beta-lactam-resistant <em>S. pneumoniae</em> [<a href="#rid15">15</a>]. If susceptibility studies of the isolated pneumococcus show intermediate susceptibility or resistance (MIC ≥1 mcg/mL) to ceftriaxone and <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, rifampin may be continued or added if the organism is susceptible to rifampin [<a href="#rid7">7</a>].</p><p>The duration of antimicrobial therapy for pneumococcal meningitis is usually 10 to 14 days.</p><p class="headingAnchor" id="H10"><span class="h3">Alternative agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">Chloramphenicol</a> (1.5 g IV every six hours) has been used in patients with pneumococcal meningitis who are allergic to penicillin and cephalosporins. However, many penicillin-resistant strains are also somewhat resistant to chloramphenicol killing (despite in vitro tests that show inhibition), and treatment failures of meningitis due to penicillin-resistant <em>S. pneumoniae</em> have occurred when chloramphenicol is used. One series evaluated 25 children with pneumococcal meningitis who had in vitro sensitivity to and were treated with chloramphenicol; 20 (80 percent) had an unsatisfactory outcome [<a href="#rid16">16</a>].</p><p>The older fluoroquinolones have generally lacked sufficient activity against <em>S. pneumoniae</em> to warrant their use in the therapy of pneumococcal meningitis, but the newer fluoroquinolones, such as <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, have shown excellent in vitro activity and efficacy in animal models of pneumococcal meningitis [<a href="#rid17">17,18</a>]. However, clinical data are sparse. One fluoroquinolone, trovafloxacin, was compared with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, with or without <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, in a multicenter randomized trial of 311 children with bacterial meningitis in which 27 percent of cases had pneumococcal meningitis [<a href="#rid19">19</a>]. The overall efficacy (CSF sterilization and clinical success) of both treatment groups was similar. Trovafloxacin is no longer utilized because of its association with serious liver toxicity, although these results suggest the potential usefulness of newer fluoroquinolones in the treatment of bacterial meningitis.</p><p>Although there are not sufficient data to recommend fluoroquinolones as part of the routine treatment of pneumococcal meningitis, this class is sometimes used in patients with serious allergies to cephalosporins or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. If it is not possible to use cephalosporins or vancomycin, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> is probably the best choice as a second agent given its excellent in vitro activity and CSF penetration. For example, in a patient with a serious cephalosporin allergy, moxifloxacin should be used in combination with vancomycin. Conversely, in a patient with a serious vancomycin allergy, moxifloxacin should be used in combination with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, if the cefotaxime or ceftriaxone MIC is ≥1 mcg/mL. </p><p class="headingAnchor" id="H11"><span class="h2">Neisseria meningitidis</span><span class="headingEndMark"> — </span>Third-generation cephalosporins, such as <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, should be used to treat suspected (eg, Gram stain with gram-negative diplococci) or culture-proven meningococcal infection prior to susceptibility results [<a href="#rid7">7</a>]. If the organism is proven to be penicillin susceptible, the treatment can then be switched to <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>. The treatment of meningococcal meningitis is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Treatment of meningitis and sepsis'</a>.)</p><p>A seven-day duration of therapy is adequate for meningococcal meningitis. However, there may still be nasopharyngeal colonization with the infecting strain. As a result, the index patient may need to take an agent that eradicates colonization (eg, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>) to avoid transmission to others. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antimicrobial chemoprophylaxis'</a>.)</p><p>Droplet precautions should be used for 24 hours after starting effective antimicrobial therapy in patients with suspected or confirmed <em>N. meningitidis</em> infection [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Haemophilus influenzae</span><span class="headingEndMark"> — </span>A third-generation cephalosporin (either <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) is the drug of choice for <em>H. influenzae</em> meningitis in adults. We recommend ceftriaxone (2 g IV twice daily) or cefotaxime (2 g IV every four to six hours) for at least seven days. If the organism does not produce beta-lactamase, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> is also an effective therapy. </p><p>The best data supporting this recommendation come from randomized trials in children. One such trial compared <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> with <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a> (a second-generation cephalosporin with good CSF penetration) in children with bacterial meningitis, which was due to <em>H. influenzae</em> in the majority of cases [<a href="#rid20">20</a>]. Ceftriaxone was significantly more likely to sterilize the CSF at 24 hours (100 versus 90 percent) and was associated with a lesser likelihood of hearing impairment at the conclusion of therapy (11 versus 18 percent). Virtually identical findings were noted in a second randomized trial comparing these two drugs [<a href="#rid21">21</a>].</p><p>Pharyngeal colonization persists after curative therapy and may require a short course of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> if there are children in the household at risk for invasive <em>Haemophilus </em>infection. This is a rare situation because conjugate vaccines for <em>H. influenzae</em> type b are widely used and highly effective. (See <a class="local">'Chemoprophylaxis'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Listeria monocytogenes</span><span class="headingEndMark"> — </span><em>Listeria</em>, a gram-positive bacillus, is an important cause of bacteremia and meningitis, particularly in older adults (in whom it accounts for approximately 20 percent of cases [<a href="#rid22">22</a>]), pregnant women [<a href="#rid23">23</a>], and patients with impaired cell-mediated immunity [<a href="#rid24">24</a>]. When <em>Listeria</em> invades the bloodstream, it has a tropism for the CNS [<a href="#rid25">25</a>]. It is more likely than other causes of meningitis to cause small brain abscesses, especially in the midbrain and brainstem [<a href="#rid26">26</a>]. These lesions can account for many of the long-term sequelae of listerial meningitis. (See  <a class="medical medical_review" href="/z/d/html/1277.html" rel="external">"Clinical manifestations and diagnosis of Listeria monocytogenes infection"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Drugs of choice</span><span class="headingEndMark"> — </span><em>Listeria</em> has traditionally been treated with <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (2 g every four hours) or <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (4 million units every four hours), since resistance to these drugs is rare [<a href="#rid27">27</a>]. <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">Gentamicin</a> is added for synergy, despite its poor penetration into the CSF [<a href="#rid28">28</a>]. The gentamicin dose (5 mg/kg per day in a person with normal renal function) is divided into three equal doses. Gentamicin has not been studied as a synergistic drug with any therapy other than the penicillin or ampicillin. Adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> should be avoided because it has been associated with higher mortality [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults", section on 'Developed regions'</a>.)</p><p><a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">Ampicillin</a> is given for at least 21 days in patients with <em>Listeria</em> meningitis; <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is given until the patient improves (for at least the first week) or, in poor responders, for up to three weeks if there are no signs of nephrotoxicity or ototoxicity. Patients with cerebritis or rhombencephalitis should be treated for at least six weeks. (See  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Alternative regimens</span><span class="headingEndMark"> — </span>If a penicillin- or cephalosporin-allergic patient cannot be desensitized to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, an alternative therapy is <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) [<a href="#rid7">7,30</a>]. </p><p>A more detailed discussion of alternative regimens for the treatment of CNS listeriosis is found in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Alternatives to ampicillin or penicillin'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Gram-negative bacilli</span><span class="headingEndMark"> — </span>Aerobic gram-negative bacilli, such as <em>Escherichia coli</em> and <em>Klebsiella</em> species, are rare causes of community-acquired meningitis in adults but are more commonly a cause of health care-associated infections, mostly following neurosurgical procedures. Gram negative bacillary meningitis can also be seen as part of the disseminated <em>Strongyloides stercoralis</em> infection in immunosuppressed individuals [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults", section on 'Risk factors'</a>.)</p><p>When culture results indicate a gram-negative bacillus, the regimen should be tailored to results of in vitro susceptibility testing, using agents that have good CNS penetration [<a href="#rid8">8</a>]. Antibiotic choices are outlined below based on susceptibility. The minimum duration of therapy is 10 to 14 days, although some experts prefer to treat for 21 days.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For Enterobacterales (such as </strong><strong><em>Escherichia coli</em></strong><strong>, </strong><strong><em>Klebsiella pneumoniae</em></strong><strong>) or other gram-negative bacilli that are susceptible to third-generation cephalosporins</strong> – We suggest <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g IV every four to six hours) or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g IV every 12 hours). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For Enterobacterales known to have inducible beta-lactamase production (eg, </strong><strong><em>Enterobacter</em></strong><strong>)</strong> – We suggest <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (2 g IV every eight hours). <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (15 to 20 mg/kg per day divided every six to eight hours based upon the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component) is another option.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For susceptible </strong><strong><em>P. aeruginosa</em></strong><strong> isolates</strong> – We suggest a single active antipseudomonal agent, preferably <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> (2 g IV every eight hours) or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (2 g IV every eight hours). Other options include <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (2 g IV every eight hours), <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (400 mg IV every eight hours), or <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every 6 hours). The addition of an aminoglycoside to any of these agents is not necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For organisms resistant to cephalosporins but susceptible to other agents (eg, if they produce an extended-spectrum beta-lactamase)</strong> – We suggest <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (2 g IV every eight hours) if the organism is susceptible. Other alternatives such as <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (400mg IV every eight hours), <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (15 to 20 mg/kg per day divided every six to eight hours based upon the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component), or <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every 6 hours) can be chosen based upon susceptibility testing [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For carbapenem-resistant organisms</strong> – These organisms are typically resistant to multiple agents in addition to carbapenems, and consultation with an expert in infectious diseases is recommended. </p><p></p><p class="bulletIndent1">Potential options that may have activity against carbapenem-resistant organisms, depending on the organism, include <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, and (where the parenteral form is available) <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>. Clinical data supporting use of these agents for meningitis or ventriculitis are limited to case series, and CSF levels achieved are not well studied, but they are generally the only active agents for such infections. Intrathecal or intraventricular antimicrobial therapy may be warranted as adjunctive therapy in cases of highly resistant gram-negative infection. In particular, if a polymyxin is warranted for a carbapenem-resistant meningitis or ventriculitis, we give <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> (usually formulated as colistimethate sodium) through the intrathecal or intraventricular route because it does not achieve sufficient CSF levels. (See  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.) </p><p></p><p class="bulletIndent1">Antibiotic selection for specific carbapenem-resistant organisms is discussed elsewhere.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Approach to treatment'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Management of multidrug-resistant organisms'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">"Acinetobacter infection: Treatment and prevention", section on 'Meningitis'</a>.)</p><p></p><p>Overall, clinical data supporting these choices are limited, particularly for health care-associated gram-negative infections. Since use of bacteriostatic antibiotics is associated with poor clinical outcome [<a href="#rid33">33</a>], agents with bactericidal activity are preferred. Bactericidal activity in the CSF is affected by the penetration, concentration, and intrinsic activity of the antibiotic, but the minimum concentration of an antibiotic in the CSF needed for bactericidal activity is controversial [<a href="#rid34">34</a>]. We agree with other experts that antibiotic regimens should achieve CSF levels 10 or more times above the minimum bactericidal concentration (MBC) of the organism [<a href="#rid35">35</a>]. </p><p>Broad-spectrum cephalosporins, such as <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, and <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, are the treatment of choice for susceptible gram-negative bacillary meningitis primarily because they have good activity against these organisms and penetrate well into the CSF [<a href="#rid34">34,36</a>]. Small clinical series, mainly in children, have described clinical cure rates of 70 to 90 percent for treatment of susceptible gram-negative bacilli with these cephalosporins [<a href="#rid37">37-39</a>]. Cefpirome is a broad-spectrum cephalosporin that is not available in the United States or Australia but may be used in other countries; it reaches CSF levels sufficient to treat susceptible gram-negative pathogens, and its spectrum of activity includes <em>Pseudomonas aeruginosa</em> [<a href="#rid40">40,41</a>]. </p><p>Carbapenems also penetrate well into the CSF [<a href="#rid42">42,43</a>] but because of antimicrobial stewardship concerns, are generally reserved for infections when cephalosporins cannot be used. The carbapenems have overall good efficacy, comparable to that of the cephalosporins, in the treatment of meningitis in both children and adults [<a href="#rid42">42,44</a>]. Of the carbapenems, we generally prefer <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. Use of imipenem-cilastatin is limited by potential for seizures; in one study of pediatric patients with meningitis, 33 percent developed seizure activity following imipenem-cilastatin administration [<a href="#rid45">45</a>]. Seizures have also been reported with <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a> when used in the setting of CNS disorders [<a href="#rid46">46</a>]. Moreover, ertapenem has a narrower spectrum than either meropenem or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> and is not active against <em>P. aeruginosa</em> or <em>Acinetobacter</em> spp. </p><p>As above, alternative options for susceptible isolates in patients who cannot use cephalosporins or carbapenems include <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and TMP-SMX. Aztreonam has excellent CSF penetration into either inflamed or uninflamed meninges and reaches CSF levels adequate for treatment of meningitis caused by most gram-negative bacilli [<a href="#rid47">47-50</a>]. Small clinical series have described good outcomes with aztreonam used for various gram-negative pathogens. Ciprofloxacin is highly active in vitro against most susceptible gram-negative organisms that cause meningitis and high cure rates (80 to 90 percent) have been reported in small series and case reports [<a href="#rid51">51-54</a>]. However, because it has variable penetration into the CSF [<a href="#rid51">51</a>], we reserve it for when first-line agents cannot be used. <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> reportedly achieves high CSF concentrations based on data on tuberculous meningitis; however, there is limited clinical evidence on moxifloxacin use for gram-negative bacillary meningitis [<a href="#rid55">55-57</a>]. TMP-SMX penetrates well into the CSF and has bactericidal activity in vitro against numerous gram-negative bacilli that cause meningitis [<a href="#rid36">36,58</a>]. However, consistent bactericidal activity has not been shown for some organisms, including <em>Klebsiella</em> and <em>Providencia</em>, and treatment failures have been reported [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3468843192"><span class="h2">Staphylococcus aureus</span><span class="headingEndMark"> — </span><em>Staphylococcus aureus</em> meningitis is typically associated with penetrating head trauma or neurosurgery [<a href="#rid7">7</a>]. Given substantial rates of methicillin-resistant <em>S. aureus</em> (MRSA), <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 3</a>) should be used as initial therapy when <em>S. aureus</em> is suspected or proven  (<a class="graphic graphic_table graphicRef71968" href="/z/d/graphic/71968.html" rel="external">table 4</a>) [<a href="#rid7">7,59</a>]. If susceptibility testing reveals methicillin-susceptible <em>S. aureus </em>(MSSA), therapy should be changed to <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> (2 g IV every four hours) or <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> (2 g IV every four hours)  (<a class="graphic graphic_table graphicRef60707" href="/z/d/graphic/60707.html" rel="external">table 1B</a>). <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a> should <strong>not</strong> be used for MSSA meningitis because it does not adequately penetrate into the CNS. If the organism is methicillin resistant, vancomycin should be continued.(See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a>.) </p><p>The duration of therapy for <em>S. aureus</em> meningitis is 10 to 14 days; the precise duration is based on clinical response [<a href="#rid59">59</a>]. We treat for 14 days if <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is administered. Removal of any CSF device, if present, is advised as retention is associated with higher mortality [<a href="#rid60">60,61</a>].</p><p>A significant drawback to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is its poor penetration into the CSF of approximately 1 and 5 percent with uninflamed and inflamed meninges, respectively [<a href="#rid59">59,60,62,63</a>]. <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> can be added to vancomycin at a dose of 600 mg orally or IV once daily or 300 to 450 mg twice daily because it achieves bactericidal concentrations in the cerebrospinal fluid regardless of meningeal inflammation [<a href="#rid7">7,59,64</a>], although there are few data to support this [<a href="#rid65">65-67</a>].</p><p>Although there are insufficient data regarding the efficacy of alternative agents for the treatment of meningitis caused by MRSA, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (usually combined with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>), and TMP-SMX are reasonable options when <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> cannot be used or is ineffective. If the patient's MRSA isolate has a vancomycin MIC ≥1 mcg/mL and the patient has not had an appropriate clinical or microbiologic response, one of the alternative regimens can be used [<a href="#rid8">8</a>]. Linezolid has good CSF penetration of approximately 66 percent [<a href="#rid59">59,68-70</a>], and TMP-SMX has moderately good CSF penetration (13 to 53 percent for TMP and 17 to 63 percent for SMX) [<a href="#rid58">58,59,71</a>]. In a rabbit meningitis model, CSF daptomycin penetration was 5 to 6 percent and achieved adequate concentrations [<a href="#rid59">59,72,73</a>]. Based upon case reports and case series of patients with CNS infections caused by MRSA, alternatives to vancomycin include linezolid (600 mg IV twice daily) [<a href="#rid74">74-77</a>], TMP-SMX (5 mg/kg of the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component IV every 8 to 12 hours) [<a href="#rid58">58,59,78</a>], and daptomycin (6 to 10 mg/kg IV once daily) usually combined with rifampin [<a href="#rid79">79</a>]. <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> has also been successfully used in two patients with MRSA meningitis, one with a ventriculoperitoneal shunt infection and the other with MRSA bacteremia and meningitis who was also treated with rifampicin during the initial two weeks of therapy [<a href="#rid80">80-82</a>]. Further studies are needed to establish the benefit of these agents for the treatment of meningitis.</p><p class="headingAnchor" id="H1885296772"><span class="h2">Streptococcus agalactiae</span><span class="headingEndMark"> — </span><em>S. agalactiae</em> (group B streptococcus) is an uncommon cause of meningitis in adults. (See  <a class="medical medical_review" href="/z/d/html/3171.html" rel="external">"Group B streptococcal infections in nonpregnant adults", section on 'Meningitis'</a>.)</p><p>Initial therapy in patients with normal renal function includes <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (2 g IV every four hours) or <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (4 million units IV every four hours). A third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>) is an alternative agent. For patients who cannot take penicillin or cephalosporins, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is suggested.</p><p>The duration of therapy is usually 14 to 21 days depending on clinical response.</p><p class="headingAnchor" id="H18"><span class="h1">REGIMENS IN PATIENTS WITH DRUG ALLERGIES</span><span class="headingEndMark"> — </span>The approach to therapy in patients with antimicrobial allergies is challenging, given the importance of early initiation of therapy and the role of beta-lactam antimicrobial regimens in the therapy of bacterial meningitis. Although it is optimal to desensitize patients with a history of anaphylaxis to beta-lactams who require therapy with this antimicrobial class, an alternative regimen must be used while the desensitization is being performed. Furthermore, the decision of whether a beta-lactam is a necessary part of the regimen is based on the Gram stain and/or culture data, the latter of which can take several days to yield an organism.</p><p>For some bacteria, regimens that do not include a beta-lactam are sufficient but, for others, a beta-lactam is the optimal therapy. (See <a class="local">'Alternative agents'</a> above and <a class="local">'Listeria monocytogenes'</a> above.)</p><p class="headingAnchor" id="H19"><span class="h1">OUTPATIENT THERAPY</span><span class="headingEndMark"> — </span>Continuing antimicrobial therapy as an outpatient may be appropriate for selected patients with bacterial meningitis. When complications occur, they usually happen within the first two to three days of therapy, although delayed cerebral injury (characterized by neurologic deterioration several days after presentation) has been reported in up to 4 percent of patients with bacterial meningitis [<a href="#rid83">83</a>]. Treatment outside of the hospital leads to decreased costs of hospitalization, decreased risk of development of nosocomial infections, and improved quality of life. Patients who are candidates for outpatient therapy should continue to receive intravenous antimicrobials for the entire course.</p><p>Caution is advised when determining appropriate candidates for outpatient therapy. The following criteria have been suggested as a guide for outpatient antimicrobial therapy in patients with bacterial meningitis [<a href="#rid7">7,84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient therapy for &gt;6 days</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of fever for at least 24 to 48 hours prior to initiation of outpatient therapy</p><p class="bulletIndent1"><span class="glyph">●</span>No significant neurologic dysfunction, focal findings, or seizure activity</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical stability or improving infection</p><p class="bulletIndent1"><span class="glyph">●</span>Ability to take fluids by mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Access to home health nursing for antimicrobial administration</p><p class="bulletIndent1"><span class="glyph">●</span>Reliable intravenous line and infusion device (if needed)</p><p class="bulletIndent1"><span class="glyph">●</span>Daily availability of a physician</p><p class="bulletIndent1"><span class="glyph">●</span>Established plan for physician visits, nurse visits, laboratory monitoring, and emergencies</p><p class="bulletIndent1"><span class="glyph">●</span>Patient and/or family compliance</p><p class="bulletIndent1"><span class="glyph">●</span>Safe environment with access to a telephone, utilities, food, and refrigerator</p><p></p><p class="headingAnchor" id="H20"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Some forms of bacterial meningitis can be prevented by successful vaccination, and temporary protection can be provided in certain cases with chemoprophylaxis.</p><p class="headingAnchor" id="H21"><span class="h2">Vaccines</span><span class="headingEndMark"> — </span>Among the major causes of bacterial meningitis in adults, vaccines are available for <em>S. pneumoniae</em>, <em>N. meningitidis</em>, and <em>H. influenzae</em>. Vaccines against <em>S. pneumoniae</em> and <em>N. meningitidis </em>are recommended for adults with a variety of risk factors for infection. Routine immunization of adults against <em>H. influenzae</em> type b is not recommended, except for those with prior splenectomy. The indications for vaccination are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Chemoprophylaxis</span></p><p class="headingAnchor" id="H23"><span class="h3">Specific organisms</span><span class="headingEndMark"> — </span>There is a role for postexposure chemoprophylaxis to prevent spread of meningococcal and <em>Haemophilus</em> meningitis under certain circumstances but not for pneumococcal disease. Indications for chemoprophylaxis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antimicrobial chemoprophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Postexposure chemoprophylaxis'</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Basilar skull fracture and cerebrospinal fluid leak</span><span class="headingEndMark"> — </span>We recommend against using prophylactic antimicrobials in those with a basilar skull fracture and CSF leak because there is no evidence of benefit [<a href="#rid8">8</a>]. </p><p>Basilar skull fractures with underlying dural tears are associated with cerebrospinal fluid (CSF) leaks and predispose patients to meningitis because of the potential for direct communication of bacteria in the upper respiratory tract with the central nervous system. In a large prospective study, CSF leak was seen in 65 (3 percent) of 2022 episodes of community-acquired bacterial meningitis [<a href="#rid85">85</a>]. CSF leak was most commonly due to ear-nose-throat surgery or remote head trauma, and it recurred despite surgical correction of the leak and vaccination efforts. However, most CSF leaks resolve spontaneously within one week of injury and without complications; in addition, most CSF leaks following trauma are not recognized [<a href="#rid8">8,86</a>]. A meta-analysis of five randomized trials and 17 other studies (involving over 2000 patients) of antibiotic prophylaxis following basilar skull fracture concluded that routine prophylaxis is not supported by the available evidence but noted that this evidence contains methodologic shortcomings and is therefore not conclusive [<a href="#rid87">87</a>].</p><p>Among patients with a basilar skull fracture and a CSF leak who develop meningitis, the median time between the injury and the onset of meningitis is 11 days [<a href="#rid86">86,88</a>]. In patients with a basilar skull fracture and a prolonged CSF leak (&gt;7 days), an attempt should therefore be made to repair the leak [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/344.html" rel="external">"Skull fractures in adults", section on 'Basilar skull fracture'</a>.)</p><p>Patients with a CSF leak (due to either basilar skull fracture or another cause) should receive pneumococcal vaccination [<a href="#rid8">8,89</a>]. The approach to vaccination in this setting is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Approach to individuals at highest risk of pneumococcal disease'</a>.)</p><p class="headingAnchor" id="H3320752620"><span class="h3">Neurosurgery</span><span class="headingEndMark"> — </span>Perioperative antimicrobial prophylaxis is indicated for patients undergoing neurosurgery, including procedures to place CSF shunts or other hardware [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Neurosurgery'</a> and  <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts", section on 'Antibiotic prophylaxis'</a>.)</p><p class="headingAnchor" id="H1919446136"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104441.html" rel="external">"Society guideline links: Bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H10511142"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16956.html" rel="external">"Patient education: Bacterial meningitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – There are a number of general principles of antimicrobial therapy in patients with bacterial meningitis. The most important initial issues are avoidance of delay in administering therapy and the choice of drug regimen. Antimicrobial therapy, along with adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> when indicated, should be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography scan of the head is indicated to be performed before LP, immediately after blood cultures are obtained. Adjunctive dexamethasone should be given shortly before or at the same time as the first dose of antimicrobials, when indicated. General principles of initial therapy and selection of empiric antibiotics are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults", section on 'General principles of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of meningitis due to</strong><strong><em> Streptococcus pneumoniae</em></strong> – For the initial therapy of <em>S. pneumoniae</em>, we recommend <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> <strong>plus either</strong> <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> <strong>or</strong> <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> rather than a third-generation cephalosporin alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In countries where the incidence of ceftriaxone-resistant pneumococcus is &lt;1 percent, it is appropriate to use ceftriaxone monotherapy for empiric coverage although some authorities would recommend continuation of dual therapy until the results of in vitro susceptibility testing are available. (See <a class="local">'First-line regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the isolate is proven to be susceptible to penicillin (minimum inhibitory concentration [MIC] ≤0.06 mcg/mL), monotherapy with <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> can be used. It is also reasonable to continue therapy with a third-generation cephalosporin alone instead of changing to penicillin or ampicillin, given the excellent efficacy, convenient dosing, and affordability of these agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the isolate is resistant to penicillin (MIC ≥0.12 mcg/mL), but susceptible to third-generation cephalosporins (MIC &lt;1.0 mcg/mL), either <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> should be used. However, if the isolate is resistant to both penicillin and third-generation cephalosporins, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus a third-generation cephalosporin should be continued for the total duration of therapy  (<a class="graphic graphic_table graphicRef81209 graphicRef60707" href="/z/d/graphic/81209.html" rel="external">table 1A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of meningitis due</strong> <strong><em>N. meningitidis</em></strong><em> </em>– For the initial therapy of <em>N. meningitidis</em>, we recommend a third-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, rather than penicillin, while awaiting susceptibility data  (<a class="graphic graphic_table graphicRef75922 graphicRef60707" href="/z/d/graphic/75922.html" rel="external">table 1B-C</a>) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). If the isolate is susceptible to penicillin, either a third-generation cephalosporin or penicillin may be used to complete the course of therapy  (<a class="graphic graphic_table graphicRef81209 graphicRef60707" href="/z/d/graphic/81209.html" rel="external">table 1A-B</a>). (See <a class="local">'Neisseria meningitidis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of</strong> <strong>other pathogens</strong> – The preferred regimens for other causes of bacterial meningitis are discussed above  (<a class="graphic graphic_table graphicRef75922 graphicRef60707" href="/z/d/graphic/75922.html" rel="external">table 1B-C</a> and <a class="graphic graphic_table graphicRef81209 graphicRef60707" href="/z/d/graphic/81209.html" rel="external">table 1A-B</a>). (See <a class="local">'Haemophilus influenzae'</a> above and <a class="local">'Listeria monocytogenes'</a> above and <a class="local">'Gram-negative bacilli'</a> above and <a class="local">'Staphylococcus aureus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations in patients with drug allergies</strong> – The optimal regimens for patients with severe drug allergies depends upon the organism. (See <a class="local">'Alternative agents'</a> above and <a class="local">'Listeria monocytogenes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of meningitis due to certain pathogens</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Certain interventions may reduce the risk of developing meningitis. As examples, vaccines against <em>N. meningitidis and S. pneumoniae are re</em>commended for adults at increased risk of these infections. In addition, there is a role for postexposure chemoprophylaxis to prevent spread of meningococcal and <em>Haemophilus mening</em>itis under certain circumstances. (See <a class="local">'Chemoprophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By contrast, for patients with a basilar skull fracture and a CSF leak, we recommend against using prophylactic antimicrobials (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). If the CSF leak persists for &gt;7 days, an attempt should be made to repair it. (See <a class="local">'Basilar skull fracture and cerebrospinal fluid leak'</a> above.)</p><p></p><p class="bulletIndent2">Patients with a CSF leak (due to either basilar skull fracture or another cause) should receive pneumococcal vaccination. The approach to vaccination in this setting is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Approach to individuals at highest risk of pneumococcal disease'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.</a></li><li><a class="nounderline abstract_t">Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.</a></li><li><a class="nounderline abstract_t">Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.</a></li><li><a class="nounderline abstract_t">Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA 1999; 282:175.</a></li><li><a class="nounderline abstract_t">Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467.</a></li><li><a class="nounderline abstract_t">Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14:813.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012; 380:1693.</a></li><li><a class="nounderline abstract_t">París MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39:2171.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. Nat Rev Dis Primers 2016; 2:16074.</a></li><li><a class="nounderline abstract_t">John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994; 18:188.</a></li><li><a class="nounderline abstract_t">Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38:918.</a></li><li><a class="nounderline abstract_t">Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44:250.</a></li><li><a class="nounderline abstract_t">Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39:1988.</a></li><li><a class="nounderline abstract_t">Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339:405.</a></li><li><a class="nounderline abstract_t">Cottagnoud P, Täuber MG. Fluoroquinolones in the Treatment of Meningitis. Curr Infect Dis Rep 2003; 5:329.</a></li><li><a class="nounderline abstract_t">Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 2008; 61:1328.</a></li><li><a class="nounderline abstract_t">Sáez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002; 21:14.</a></li><li><a class="nounderline abstract_t">Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964.</a></li><li><a class="nounderline abstract_t">Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.</a></li><li><a class="nounderline abstract_t">Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.</a></li><li><a class="nounderline abstract_t">Mylonakis E, Paliou M, Hohmann EL, et al. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore) 2002; 81:260.</a></li><li><a class="nounderline abstract_t">Skogberg K, Syrjänen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis 1992; 14:815.</a></li><li><a class="nounderline abstract_t">Büla CJ, Bille J, Glauser MP. An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis 1995; 20:66.</a></li><li><a class="nounderline abstract_t">Dee RR, Lorber B. Brain abscess due to Listeria monocytogenes: case report and literature review. Rev Infect Dis 1986; 8:968.</a></li><li><a class="nounderline abstract_t">Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10:300.</a></li><li><a class="nounderline abstract_t">Cherubin CE, Appleman MD, Heseltine PN, et al. Epidemiological spectrum and current treatment of listeriosis. Rev Infect Dis 1991; 13:1108.</a></li><li><a class="nounderline abstract_t">Hasbun R. Update and advances in community acquired bacterial meningitis. Curr Opin Infect Dis 2019; 32:233.</a></li><li><a class="nounderline abstract_t">Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986; 8:427.</a></li><li><a class="nounderline abstract_t">Hosoda T, Sakamoto M, Orikasa H, et al. Septic Meningitis and Liver Abscess due to Hypermucoviscous Klebsiella pneumoniae Complicated with Chronic Strongyloidiasis in a Human T-lymphotropic Virus 1 Carrier. Intern Med 2020; 59:129.</a></li><li><a class="nounderline abstract_t">Sáez-Llorens X, Castaño E, García R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995; 39:937.</a></li><li><a class="nounderline abstract_t">Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.</a></li><li><a class="nounderline abstract_t">Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708.</a></li><li><a class="nounderline abstract_t">Corrado ML, Gombert ME, Cherubin CE. Designing appropriate therapy in the treatment of gram-negative bacillary meningitis. JAMA 1982; 248:71.</a></li><li><a class="nounderline abstract_t">Rahal JJ, Simberkoff MS. Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis. Ann Intern Med 1982; 96:468.</a></li><li><a class="nounderline abstract_t">Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.</a></li><li><a class="nounderline abstract_t">Rodriguez WJ, Khan WN, Cocchetto DM, et al. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Pediatr Infect Dis J 1990; 9:83.</a></li><li><a class="nounderline abstract_t">Landesman SH, Corrado ML, Shah PM, et al. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. Am J Med 1981; 71:693.</a></li><li><a class="nounderline abstract_t">Wolff M, Chavanet P, Kazmierczak A, et al. Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. J Antimicrob Chemother 1992; 29 Suppl A:59.</a></li><li><a class="nounderline abstract_t">Friedland IR, Sultan E, Lehr KH, Lenfant B. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob Agents Chemother 1998; 42:199.</a></li><li><a class="nounderline abstract_t">Klugman KP, Dagan R. Carbapenem treatment of meningitis. Scand J Infect Dis Suppl 1995; 96:45.</a></li><li><a class="nounderline abstract_t">Jacobs RF, Kearns GL, Brown AL, Longee DC. Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections. Antimicrob Agents Chemother 1986; 29:670.</a></li><li><a class="nounderline abstract_t">Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.</a></li><li><a class="nounderline abstract_t">Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10:122.</a></li><li><a class="nounderline abstract_t">Fica AE, Abusada NJ. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis 2008; 40:983.</a></li><li><a class="nounderline abstract_t">Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis 1991; 13 Suppl 7:S586.</a></li><li><a class="nounderline abstract_t">Trujillo H, Harry N, Arango A, et al. Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. Chemotherapy 1989; 35 Suppl 1:25.</a></li><li><a class="nounderline abstract_t">Feris J, Moledina N, Rodriguez WJ, et al. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections. Chemotherapy 1989; 35 Suppl 1:31.</a></li><li><a class="nounderline abstract_t">Stutman HR, Welch DF, Scribner RK, Marks MI. In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients. Antimicrob Agents Chemother 1984; 25:212.</a></li><li><a class="nounderline abstract_t">Krcméry V Jr, Filka J, Uher J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999; 35:75.</a></li><li><a class="nounderline abstract_t">Schönwald S, Beus I, Lisić M, et al. Ciprofloxacin in the treatment of gram-negative bacillary meningitis. Am J Med 1989; 87:248S.</a></li><li><a class="nounderline abstract_t">Green SD, Ilunga F, Cheesbrough JS, et al. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect 1993; 26:253.</a></li><li><a class="nounderline abstract_t">Lipman J, Allworth A, Wallis SC. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000; 31:1131.</a></li><li><a class="nounderline abstract_t">Reddy P, Das S, Chandler JP, Noskin GA. Stenotrophomonas maltophilia meningitis treated with moxifloxacin: a case report and review of the literature. Infect Dis Clin Practice 2006; 14:173.</a></li><li><a class="nounderline abstract_t">Sáez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am 1999; 13:619.</a></li><li><a class="nounderline abstract_t">Alffenaar JW, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49:1080.</a></li><li><a class="nounderline abstract_t">Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449.</a></li><li><a class="nounderline abstract_t">Pintado V, Pazos R, Jiménez-Mejías ME, et al. Staphylococcus aureus meningitis in adults: A comparative cohort study of infections caused by meticillin-resistant and meticillin-susceptible strains. J Hosp Infect 2019; 102:108.</a></li><li><a class="nounderline abstract_t">Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040.</a></li><li><a class="nounderline abstract_t">Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008; 69:126.</a></li><li><a class="nounderline abstract_t">Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719.</a></li><li><a class="nounderline abstract_t">Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.</a></li><li><a class="nounderline abstract_t">von Specht M, Gardella N, Tagliaferri P, et al. Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006; 25:267.</a></li><li><a class="nounderline abstract_t">Pintado V, Meseguer MA, Fortún J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.</a></li><li><a class="nounderline abstract_t">Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.</a></li><li><a class="nounderline abstract_t">Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51:379.</a></li><li><a class="nounderline abstract_t">Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother 2008; 14:147.</a></li><li><a class="nounderline abstract_t">Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984; 26:811.</a></li><li><a class="nounderline abstract_t">Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57:720.</a></li><li><a class="nounderline abstract_t">Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.</a></li><li><a class="nounderline abstract_t">Gallagher RM, Pizer B, Ellison JA, Riordan FA. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57:410.</a></li><li><a class="nounderline abstract_t">Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007; 35:271.</a></li><li><a class="nounderline abstract_t">Naesens R, Ronsyn M, Druwé P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009; 58:1247.</a></li><li><a class="nounderline abstract_t">Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.</a></li><li><a class="nounderline abstract_t">Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005; 33:36.</a></li><li><a class="nounderline abstract_t">Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.</a></li><li><a class="nounderline abstract_t">Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis 2017; 4:ofx084.</a></li><li><a class="nounderline abstract_t">Kuriakose SS, Rabbat M, Gallagher JC. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother 2015; 70:953.</a></li><li><a class="nounderline abstract_t">Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother 2015; 70:624.</a></li><li><a class="nounderline abstract_t">Gallegos C, Tobolowsky F, Nigo M, Hasbun R. Delayed Cerebral Injury in Adults With Bacterial Meningitis: A Novel Complication of Adjunctive Steroids? Crit Care Med 2018; 46:e811.</a></li><li><a class="nounderline abstract_t">Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394.</a></li><li><a class="nounderline abstract_t">Ter Horst L, Brouwer MC, van der Ende A, van de Beek D. Community-acquired Bacterial Meningitis in Adults With Cerebrospinal Fluid Leakage. Clin Infect Dis 2020; 70:2256.</a></li><li><a class="nounderline abstract_t">Rogers T, Sok K, Erickson T, et al. Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis. Open Forum Infect Dis 2019; 6:ofz050.</a></li><li><a class="nounderline abstract_t">Ratilal BO, Costa J, Pappamikail L, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2015; :CD004884.</a></li><li><a class="nounderline abstract_t">Choi D, Spann R. Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics. Br J Neurosurg 1996; 10:571.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.</a></li><li><a class="nounderline abstract_t">Hasbun R. Central Nervous System Device Infections. Curr Infect Dis Rep 2016; 18:34.</a></li></ol></div><div id="topicVersionRevision">Topic 1283 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432041" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dexamethasone in adults with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867727" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute bacterial meningitis in adults. A review of 493 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411200" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The rational clinical examination. Does this adult patient have acute meningitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610819" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104307" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203777" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23141618" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Advances in treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8619561" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808261" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8161625" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067771" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173226" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540704" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346668" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12866985" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fluoroquinolones in the Treatment of Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353805" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11791092" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3047581" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403654" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395430" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bacterial meningitis in the United States in 1995. Active Surveillance Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169881" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Listeriosis during pregnancy: a case series and review of 222 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1341415" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727673" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3099364" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Brain abscess due to Listeria monocytogenes: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765103" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Central nervous system infection with Listeria monocytogenes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1775844" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiological spectrum and current treatment of listeriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31021955" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Update and advances in community acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523699" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31434825" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Septic Meningitis and Liver Abscess due to Hypermucoviscous Klebsiella pneumoniae Complicated with Chronic Strongyloidiasis in a Human T-lymphotropic Virus 1 Carrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7785999" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7020416" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041103" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087095" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Designing appropriate therapy in the treatment of gram-negative bacillary meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039444" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3903939" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179845" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6269429" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1601758" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449289" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7652503" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Carbapenem treatment of meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3458427" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625802" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2062603" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Imipenem/cilastatin treatment of bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759157" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068463" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aztreonam in the treatment of gram-negative bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2731447" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2731448" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6538772" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529884" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589372" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ciprofloxacin in the treatment of gram-negative bacillary meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8505559" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073740" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Stenotrophomonas maltophilia meningitis treated with moxifloxacin: a case report and review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470558" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antimicrobial and anti-inflammatory treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712035" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6372565" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Trimethoprim-sulfamethoxazole for bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992031" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448277" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Staphylococcus aureus meningitis in adults: A comparative cohort study of infections caused by meticillin-resistant and meticillin-susceptible strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12744364" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976701" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1506352" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443255" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570137" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Methicillin-resistant Staphylococcus aureus in community-acquired meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525921" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical study of 44 cases of Staphylococcus aureus meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982782" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043116" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622679" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6335381" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16459345" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388454" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703232" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646913" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528145" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284501" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Linezolid for the treatment of patients with central nervous system infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750759" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636964" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28702467" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422288" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274007" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29746358" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Delayed Cerebral Injury in Adults With Bacterial Meningitis: A Novel Complication of Adjunctive Steroids?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585784" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Outpatient parenteral antimicrobial therapy for central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300817" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Community-acquired Bacterial Meningitis in Adults With Cerebrospinal Fluid Leakage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899767" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918919" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9115653" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27686676" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Central Nervous System Device Infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
